Trial reportAJNR. American journal of neuroradiology2003
Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.
Trial report in AJNR. American journal of neuroradiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Correlation between the clinical disability and T1 hypointense lesions' volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta-analysis.CNS neuroscience & therapeutics · 2021Pooled it
- An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.Clinical pharmacokinetics · 2021Trial
- The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.Journal of neurology · 2008Trial
- Insights from DCE-MRI: blood-brain barrier permeability in the context of MS relapses and methylprednisolone treatment.Frontiers in neuroscience · 2025Article
- Bibliometric analysis of myelin imaging studies of patients with multiple sclerosis (2000-2022).Quantitative imaging in medicine and surgery · 2024Article
- Glucocorticoid-dependent multiple sclerosis overlapping anti-NMDA receptor encephalitis: a case report and literature review update.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Review
- Predictive MRI Biomarkers in MS-A Critical Review.Medicina (Kaunas, Lithuania) · 2022Review
- The Relevance of Neuroimaging Findings to Physical Disability in Multiple Sclerosis.Noro psikiyatri arsivi · 2018Review
- Article
- T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis.PloS one · 2017Article
- Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.Therapeutic advances in neurological disorders · 2014Review
- Composite MRI scores improve correlation with EDSS in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2010Article
- Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord.Brain : a journal of neurology · 2009Article
- Imaging of multiple sclerosis: role in neurotherapeutics.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2005Review
- Biomarkers and surrogate markers: an FDA perspective.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeDespite extensive use of MR imaging to provide markers of multiple sclerosis (MS) activity and accumulated disease burden, the magnitude of the relationship between clinical and MR findings is still debated. Using data from the European/Canadian glatiramer acetate (GA) trial, we investigated short-term correlations between clinical and MR measures of disease activity in patients with relapsing-remitting MS (RRMS).
methodsIn a 9-month, double-blinded, placebo-controlled study, 239 patients with RRMS were randomly assigned to receive 20 mg GA (n = 119) or placebo (n = 120). Clinical assessment included monthly neurologic examinations with Expanded Disability Status Scale scoring and visits for symptoms suggestive of relapse. Dual-echo T2-weighted and pre- and postcontrast T1-weighted brain MR images were obtained at baseline and monthly during follow-up. Contrast-enhancing and new T2-hyperintense lesions were counted, and total T2-hyperintense and T1-hypointense lesion volumes were measured.
resultsSignificant univariate correlations were found between the number of relapses during the study period and the number of enhancing lesions at baseline (r = 0.25) and during follow-up (r = 0.30) in the study population as a whole. Multivariable analysis showed that two independent factors were more strongly correlated with relapse frequency: the number of relapses during the 2 years before entry and the number of on-trial enhancing lesions, in the whole study population and in the placebo group.
conclusionIn RRMS, MR imaging measures of inflammatory activity are modestly but significantly correlated with the occurrence of clinical attacks over the short term. Clinical and MR imaging assessment can provide complementary outcome measures for RRMS trials.
Indexed as
Identifiers
12533330PMC8148965W2106266085What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.